Floatz logo

Tak-228

Stage IV Lung Cancer AJCC v8

M.D. Anderson Cancer CenterPhase 1/2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Stage IV Lung Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Atezolizumab
University of Washington
Phase 4BB
Osimertinib
Beijing Pearl Biotechnology Limited Liability Company
Phase 3BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
University of Chicago
Phase 2/3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
University of Chicago
Phase 3BB
Sotorasib
National Cancer Institute (NCI)
Phase 2B

View all 38 →

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Recurrent Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →